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Medicine use in older adults (Part I) 
 
Maurice Hall and Lezley-Anne Hanna 
Lecturer (Education) and Senior Lecturer (Education), respectively; Queen’s University Belfast 
 
After completing this part of the module you will:  
• know the accepted age of an ‘elderly’ or ‘older adult’ 
• have an awareness of some statistics relating to older population and life expectancy 
• understand pharmacokinetic changes that occur in older adults (in terms of absorption, 
distribution, metabolism and excretion) 
•  describe pharmacodynamic changes that occur in older adults and appreciate the relevance 
of this when considering drug use and potential adverse effects 
 
Most developed countries have accepted the chronological age of 65 years as a definition of 'elderly' 
or ‘older person’.1 The United Kingdom (UK) population is ageing, as is the case in many other 
countries across the globe.2 Indeed, the percentage of the UK population aged ≥65 years has increased 
from 15% in 1984 to 18% in 2014, which equates to an increase of over 3 million people.3 In 2014, of 
the adults aged 65 and over, 73% were between 65 and 79 years old, 22% were between 80 and 89 
years old and 5% were ≥90 years old.3 There were over 500,000 people aged ≥90 years living in the UK 
in 2014, including 14,450 centenarians.3  
 
According to the World Health Organization (WHO) in 2015, the average life expectancy at birth of the 
global population is 71.4 years.4 Most countries in western Europe (including the UK and Ireland) and 
many other developed countries such as Canada, Japan, Singapore, Australia and New Zealand have a 
life expectancy over 80 years.4 Moreover, a report by Public Health England (PHE) found that in 
England, life expectancy at older ages is now at its highest ever level. At the age of 65 years, men can 
be expected to live for a further 19 years and women another 21 years.5 Improved life expectancy over 
recent decades is due to various factors such as advances in medical interventions, improved housing 
and living standards, and better nutrition. Within the next four or five years in the UK, there is a 
predicted increase of 12% (1.1 million) people aged >65 years [those aged >85 years will increase by 
18% (300,000); and centenarians by 40% (7,000)].6  
 
Increased life expectancy has an important impact on the provision of care by the National Health 
Service (NHS). According to a Department of Health estimate in 2010, long-term conditions account 
for 70% of total health and social care spending in England, with the average cost of providing hospital 
and community health services for a person >85 years old about three times more than for a person 
who is between 65 to 74 years of age.6   Given that the prevalence of long-term conditions increases 
with age,, older people are potentially living with comorbidities that are being managed with an 
increasing number of medicines. In England in 2015, of the almost 1.1 billion prescription items 
dispensed, 60.4% of the items were for patients aged 60 years and above; up from 56.9% in 2005.7   
While taking medicines has many benefits for patients, older adults are at considerable risk of 
experiencing negative effects from taking multiple medicines including adverse drug reactions, 
interactions, non-adherence, and increased hospital admissions. The remainder of this module aims 
to discuss the ageing process and the effects these changes can have on health and also provide 
guidance on medicines management. 
 
The ageing process encompasses anatomical, physiological, psychological and sociological changes. 
Anatomical changes include: alteration of posture, bony hands because adipose tissue is lost from the 
periphery, skin becoming wrinkled and dry/dehydrated, hair thinning, greying or baldness (but new 
hair growth may develop in the ears of men or above the upper lip and chin in females), bone 
resorption, teeth being removed/lost or the enamel yellowing, nails becoming hard and thick, lean 
body mass decreasing and shrinking of many organs. Table 1 summarises some pertinent physiological 
changes. Psychological changes can be due to an organic cause or an extrinsic reason such as 
retirement, bereavement or loneliness. Older adults may also lose cognitive skills, including their 
short-term memory. Sociological factors that should be considered include a person’s economic 
situation, where they live and their housing conditions, marital status and support systems. 
 
  
Table 1  Important physiological changes in older people 
Cardiovascular  Increased arterial and myocardial stiffness 
Increased blood pressure (typically systolic) 
Gastrointestinal  Decreased gastric acid secretion 
Increased gastric emptying time 
Reduced gut motility and blood flow 
Reduced absorption surface/atrophy of the gastrointestinal villi 
Genito-urinary  Decreased glomerular filtration rate 
Decrease in renal mass and renal blood flow 
Impaired ability to handle sodium and potassium 
Incomplete bladder emptying and reduced bladder capacity 
Decrease in the pH of vaginal secretions and in vaginal secretions 
Hepatic  Reduced liver mass 
Reduced liver blood flow 
Impaired clearance of drugs that require Phase 1 metabolism 
Immune Overall function declines 
Increased likelihood and frequency of infections 
Increased prevalence of neoplasms and autoimmune disorders 
Nervous Decreased chemical transmission 
Decreased brain flow and impaired autoregulation of perfusion 
Slowed central processing and reaction time 
Cerebral atrophy 
Respiratory Less effective ciliary action and cough reflex is less effective 
Increased residual volume 
Decreased forced expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC), lung mass and muscle strength 
 
Age-related changes in pharmacokinetics (how the body handles a drug) make older people more 
susceptible to the effects of some medicines. Key summary points about pharmacokinetic changes are 
outlined in Table 2. The key pharmacokinetic parameters are summarised below:  
 Absorption – most drugs are given orally and enter into the circulation from the small intestine, 
mostly due to its very large surface area. Absorption is affected by how lipophilic the drug 
molecule is, molecular size and other factors such as the pH of the surrounding environment 
(which affects ionisation of the drug or its stability) or the presence of food.  
 Distribution – after drugs are absorbed, they are then distributed to other areas of the body 
through the circulation; they then move from the circulation into the tissues. The extent to which 
a drug stays in the circulation or moves into other compartments of the body is reflected in the 
Volume of Distribution (VD).  Large VD values normally indicate the drug resides in tissues, whereas 
small VD values indicate the drug has remained in the intravascular compartment.  
 Metabolism – all drugs absorbed from the GI tract enter the portal circulation and pass though 
the liver, where so-called “first-pass metabolism” occurs. Other routes of administration avoid 
this initial metabolism and hence are preferable for drugs where they would be rendered inactive 
if taken orally, for example, glyceryl trinitrate. Metabolism, which largely occurs in the liver, has 
two important effects. Firstly, these ‘phase one’ reactions make the drug more hydrophilic, which 
speeds up its removal by the kidneys. Secondly, it usually (but not always) produces a metabolite 
that is less pharmacologically active than its parent (pro-drugs are an obvious exception to this 
rule, for example, enalapril).  
 Excretion – most drugs and their metabolites are eliminated from the body via the kidneys. This 
elimination occurs by glomerular filtration or by tubular secretion at the proximal tubules by two 
independent carrier systems. However, many lipid-soluble drugs are reabsorbed back into the 
body from the renal tubules, whereas polar drugs become more concentrated in the urine as 
water is reabsorbed. 
 
  
Table 2 The effect of ageing on drug response (age-related pharmacokinetic changes)  
 Age-related changes Clinical effects 
Absorption 
 
 Splanchnic and mesenteric blood 
flow reduced 
 Absorptive surface reduced 
 GI motility and gastric pH reduced 
 
 The decrease in gastric emptying rate 
and gastro-intestinal motility tend to 
delay absorption, rather than reduce 
the amount of drug absorbed 
(The exception is drugs that are 
subject to first-pass metabolism). 
 
Distribution 
 
 Serum albumin is decreased 
(could be due to poor nutritional 
status) 
 Total body fat increased 
 Lean body mass and total body 
water decreased 
 Age related changes in 
distribution/protein binding 
mostly of significance in the acute 
administration of drugs as plasma 
concentration at steady state is 
determined by clearance 
 
 Higher concentrations of free drug 
drugs that bind to albumin) and 
increased therapeutic response (such 
as phenytoin)  
 Longer elimination half-life of lipid 
soluble drugs (such as diazepam) 
 Reduction in loading dose of water-
soluble drugs required (such as 
digoxin) 
Metabolism 
 
 
 Liver blood flow and hepatic mass 
deceased 
 Enzyme activity changes, 
particularly in frail older people  
 Phase 2 metabolism is usually 
unaffected by ageing 
 Decreased biotransformation and 
first-pass metabolism – for example, 
nifedipine known to have enhanced 
hypotensive effect due to impaired 
first-pass metabolism. 
Excretion 
 
 
 Renal blood flow reduced  
 Tubular secretion/reabsorption 
decreased 
 Glomerular filtration rate 
decreased 
 The BNF states that “the most 
important effect of age is reduction in 
renal clearance” 
 Decreased elimination of renally 
excreted drugs. Significance of 
reduced renal clearance depends on % 
of total drug eliminated by glomerular 
filtration/therapeutic index and may 
require dose reductions (such as 
digoxin, lithium) 
 Acute illness can lead to rapid 
reduction in renal clearance – 
especially when accompanied by 
dehydration 
 Concomitant conditions such as 
diabetes, heart failure and 
hypertension may further reduce renal 
function and hence lead to 
accumulation of drug 
 
Pharmacodynamics (the drug’s actions on a patient) can also be significantly altered with increasing 
age and together with the age-associated changes in pharmacokinetics, helps explain altered drug 
effects. There are two types of pharmacodynamic change i.e. those due to a reduction in homeostatic 
reserve and those due to changes in receptors or targets8. Reduced homeostatic reserve relates to 
physiological changes in older people that mean the actions of some drugs are more likely to cause 
problems. Examples of where the body is less able to maintain homeostasis include the following: 
orthostatic responses are lessened (causing hypotension); postural control reduced (reduction in 
dopamine receptors in the striatum may be responsible causing an increased risk of falls); 
thermoregulation impaired (leading to hypothermia); cognitive function is decreased (causing 
confusion); and smooth muscle function declines (resulting in incontinence and constipation). Some 
medicines that are likely to cause problems due to these physiological changes are outlined below: 
• Orthostatic responses: medicines more likely to cause hypotension include antihypertensives, 
tricyclics and phenothiazines. Benzodiazepines, barbiturates, morphine, levodopa and 
bromocriptine are known to reduce sympathetic effects via their action on the central nervous 
system and are therefore more likely to result in hypotension in older adults 
• Postural control: medicines that increase postural sway (such as hypnotics and tranquillizers) 
have been associated with falls 
• Thermoregulation: medicines commonly implicated in hypothermia include phenothiazines, 
benzodiazepines, tricyclic antidepressants and opioids.  
• Cognitive function: medicines such as anticholinergics, hypnotics, H2 antagonists and β 
blockers can all cause confusion. 
• Smooth muscle function: a decline in gastrointestinal motility occurs with anticholinergics, 
opiates, tricyclics and antihistamines (making constipation or ileus more likely).  
Anticholinergics can cause urinary retention, especially in older men with prostatic 
hypertrophy. Loop diuretics may cause incontinence in patients with bladder instability or 
urethral dysfunction. 
 
Responses may also be altered by changes in receptor density, affinity and post-receptor events. For 
example, α2 responsiveness appears to be reduced with ageing, while α1 remains unaffected. β 
adrenceptor function declines with age (decreased effects of both isoprenaline and propranolol have 
been noted). Changes may be due to a reduction in high-affinity binding sites or impairment of post-
receptor transduction mechanisms.  
Regarding the cholinergic system, effects are mostly unknown, but atropine may cause less 
tachycardia in older adults. Moreover, older adults are more sensitive to benzodiazepines than 
younger adults (mechanism unknown) meaning that lower doses should be used. Older adults are also 
more sensitive to warfarin (typically requiring a dose reduction) but again, the mechanism is unknown. 
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